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Abstract
Toxic epidermal necrolysis (TEN) is a life-threatening mucocutaneous reac-
tion to drugs. Lamotrigine is an antiepileptic agent not chemically related 
to the aromatic anticonvulsants that is also prescribed for mood disorder. 
Although adverse reaction from lamotrigine have been reported after a low 
initial dosage, the risk of developing TEN during lamotrigine therapy is 
rare when recommended guidelines for the dosing schedule are carefully 
followed. We present a 35-year-old woman with a mood disorder who devel-
oped TEN after about 10 days of lamotrigine (50 mg daily) monotherapy. 
She developed generalized maculopapular eruptions that progressed until 
more than 90% of her body surface area was involved, with extensive 
epidermal detachment. The lesions affected her conjunctival, oral, nasopha-
ryngeal, genital, and vaginal mucosa. Lamotrigine was immediately dis-
continued. After receiving systemic antihistamine and corticosteroid 
treatment, the patient had a complete recovery. [Tzu Chi Med J 2009; 
21(2):165–168]
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1. Introduction
Lamotrigine is an antiepileptic agent that has been 
increasingly prescribed as a mood stabilizer in bipo-
lar disorders. Like other anticonvulsant agents, lamo-
trigine can cause adverse drug reactions, including 
life-threatening Stevens-Johnson syndrome (SJS) and 
toxic epidermal necrolysis (TEN) [1–6]. This anticon-
vulsant hypersensitivity syndrome clinically includes 
severe maculopapular exanthema, fever, and lymph-
adenopathy. It can also damage internal organs such 
as the liver, kidneys and lungs, and cause hematologic 
or pulmonary impairment [4,7]. When an adverse drug 
eruption involves an extensive portion of the body 
surface area and several mucosal areas, and is then 
followed by widespread loss of skin, a diagnosis of 
SJS-TEN should be considered. SJS-TEN syndromes 
are caused by adverse drug reactions with an over-
lapping spectrum of severity that can be distinguished 
by the percentage of body surface area involved and 
mucosal involvement, rapidly followed by epidermal 
detachment [8].
We report a 35-year-old woman who developed SJS 
after taking lamotrigine at a dosage of 50 mg daily for 
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about 10 days for bipolar disorder. Her initial skin rash 
progressed to TEN.
2. Case report
A 35-year-old woman came to our dermatology clinic 
with the chief complaints of acute onset of a general-
ized skin rash, lip and oral mucosa ulcers, sore throat, 
and fever over the past 2–3 days. Physical examina-
tion showed crusted swollen lips with ulcers, oral ul-
cers, and cervical lymphadenopathy. Examination of 
her skin showed a generalized erythematous maculo-
papular rash with occasional large confluent patches 
and atypical targetoid lesions on the trunk (Fig. 1) 
and all four extremities. Her entire face was ery-
thematous (Fig. 2). She was admitted with the diag-
nosis of toxicoderma from a suspected drug eruption. 
However, the patient denied taking any medication, 
herbal medicine, traditional Chinese medicine, or 
health supplements before the present illness. She 
also denied any other chemical exposure or recent 
infections.
After she was admitted, we found that she had pre-
viously visited our psychiatric clinic, and had taken 
lamotrigine, 50 mg daily, for bipolar disorder. She 
had already taken lamotrigine for about 9–10 days 
before the constitutional symptoms of fever (38.5°C), 
sore throat, and cervical lymphadenopathy appeared. 
The skin rash developed on the next day. She kept 
taking lamotrigine because she did not correlate her 
symptoms with the drug. We discontinued lamotrig-
ine on the second day of hospitalization.
Her skin eruptions progressed for several days 
after lamotrigine was stopped, and coalesced quickly. 
Then, a full-blown skin rash developed and spread to 
more than 90% of her body surface area. Large, wide-
spread confluent erythematous, dark red or purplish 
patches, with multiple serous papules, vesicles, or 
bullae were noted. Her epidermis then turned brown-
ish and became necrotic, and finally detached in 
sheets. Nikolsky’s sign, where the top layers of the 
skin slip away from the lower layers when rubbed 
slightly, was positive. She also complained of red 
eyes with discharge, painful crusts in her nose, oral 
ulcers, swollen crusted lips, and painful genital and 
vaginal ulcers with a yellowish discharge.
A diagnosis of lamotrigine-related SJS-TEN was 
established. She received a systemic antihistamine 
(diphenhydramine, 30 mg three times daily intrave-
nously) and a corticosteroid (betamethasone, 4 mg 
twice daily intravenously) after admission. She was 
also given parenteral hydration and nutrition because 
of her oral lesions and difficulty in swallowing. We gave 
her supportive treatment with a topical corticosteroid 
and emollient to relieve her mucosal symptoms.
Her condition improved slowly. The dosage of the 
sy stemic corticosteroid was tapered gradually and 
finally stopped after 3 weeks. Her skin rash subsided 
completely and the mucosal lesions healed without 
scarring.
Laboratory tests included complete blood count 
with white cell differentiation, erythrocyte sedimenta-
tion rate, C-reactive protein, liver studies (aspartate 
aminotransferase [AST], alanine aminotransferase 
[ALT]) and kidney function test, electrolytes, plasma 
protein, antinuclear antibody, total IgA, IgG, IgM, IgE, 
and urine and stool analyses. Serum antibodies against 
antistreptolysin O and antibodies to Mycoplasma 
pneumoniae were also surveyed and both were nega-
tive. The lab results on the first hospital day showed a 
slight elevation in C-reactive protein of 2.437 mg/dL 
(normal range, 0–0.5 mg/dL), AST of 79 IU/L (normal 
range, 10–38 IU/L), and ALT of 59 IU/L (normal range, 
3–41 IU/L).
On the fourth hospital day, the following data were 
noted: AST 46 IU/L and ALT 90 IU/L. The abnormal 
Fig. 1 — Initial stage of generalized erythematous macu-
lopapular eruption on the first day of hospitalization.
Fig. 2 — Crusted erosions or ulcerations on the lips are 
almost always present in SJS-TEN, as in this patient.
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urinalysis results (occult blood, 1+; RBC, 8–10; WBC, 
2+; epithelial cells, 2–4) could have been related to 
the genital ulcers. The other tests were all negative 
or within normal ranges. Eosinophil count and IgE 
were also within normal limits. Chest film showed no 
active lung involvement and her heart size was nor-
mal. The mild liver function impairment noted could 
have resulted from lamotrigine hypersensitivity.
A skin biopsy was performed on the fourth hospital 
day. Histologically, the skin lesions showed multiple 
vesicles with full-thickness epidermal necrosis and 
sparse superficial perivascular lymphocytic infiltra-
tion (Fig. 3). This was consistent with toxic epider-
mal necrolysis.
Antibodies against herpes simplex viruses (HSV) 
were also investigated. The results were available 1 
week after the patient was discharged from hospital. 
The results included HSV type 1: IgG, high positive, 
IgM, positive; and type 2: IgG, negative, IgM, positive, 
ratio > 200. These results suggest that the patient 
might have had a concomitant HSV infection leading 
to delayed healing of her mucosal ulcers and positive 
antibodies to HSV.
3. Discussion
Lamotrigine, an antiepileptic drug of the phenyltri-
azine class, is not chemically related to other anti -
epileptic drugs. It was first released in Ireland in late 
1990 and was approved by the U.S. Food and Drug 
Administration (FDA) in 1998 as adjunctive therapy 
or monotherapy for adults or children with partial 
and generalized tonic-clonic seizures [9].
During the development of lamotrigine, the drug 
was observed to improve mood, alertness, and social 
interaction in some patients. These early observa-
tions in patients with epilepsy stimulated interest in 
the evaluation of lamotrigine as an antidepressant and 
mood stabilizer [10]. In 2003, it was approved by the 
FDA with a new indication: maintenance therapy for 
bipolar I disorder [9].
Lamotrigine can produce adverse reactions simi-
lar to the hypersensitivity syndrome caused by other 
anticonvulsants. This syndrome consists of a triad of 
fever, skin rash and multiple internal organ dysfunc-
tion that occurs 1–8 weeks after exposure to the 
causative agent [4–7,11–13]. Aromatic anticonvulsants 
(phenytoin, phenobarbital and carbamazepine) are 
the drugs most often involved in this triad. A skin rash 
appears as localized purpura, angioedema, fixed drug 
eruption [14], a maculopapular erythematous rash, 
or a serious life-threatening rash, such as in SJS and 
TEN. The multiorgan dysfunction can be asymptomatic 
or symptomatic. The liver is more frequently involved 
than other organs such as the kidneys, central ner-
vous system, lungs, heart, or thyroid. Disseminated 
intravascular coagulation has also been reported, 
but is rare [5,7].
SJS and TEN are both severe, episodic acute mu-
cocutaneous intolerance reactions, characterized by 
a rapidly expanding erythematous or purplish macular 
rash, often with atypical (flat, irregular) target lesions 
on the skin, and prominent involvement of more than 
one mucosal site. Usually, two or three mucosal sites 
(oral, conjunctival, and anogenital) are affected. In 
TEN, the rash usually coalesces to widespread ery-
thema and epidermal necrosis. Constitutional symp-
toms and severe internal organ involvement frequently 
occur. Adverse drug reactions are the main causes 
of TEN and few cases have been reported to be as-
sociated with infection, vaccination, graft-versus-host 
disease, or idiopathic causes [5,8].
In the beginning, most TEN presents as SJS. In 
fact, TEN is almost identical to SJS and the two syn-
dromes are differentiated by the extent of body sur-
face area involvement. In TEN, more than 30% of the 
skin area is involved, whereas in SJS, less than 10% 
of the skin area is affected [8].
The results of serologic studies of HSV in our pa-
tient suggested a concomitant acute HSV infection, 
and erythema multiforme should be considered in 
the differential diagnosis. The extent of the skin le-
sions and sparse inflammation in the tissue section 
favored a diagnosis of SJS-TEN rather than erythema 
multiforme.
Patients with severe SJS or TEN should be treated in 
an intensive care unit or burn center. The risk of death 
is significant and the patient’s outcome depends on 
the severity of the disease and the quality of medical 
care. A minimum battery of laboratory tests, such as 
Fig. 3 — Skin biopsy from the trunk shows basal vacuola-
tion, frequent dyskeratosis, and extensive epidermal 
necrosis with sparse inflammation (hematoxylin & eosin, 
100˜).
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liver transaminase levels, complete blood count, uri-
nalysis and serum creatinine levels, should be or-
dered. General supportive treatment should include 
immediate withdrawal of the offending drug, careful 
fluid and nutritional support, whole-body skin lesion 
care with dressings to prevent secondary bacterial 
infection, and pain control. Systemic corticosteroids 
should be administered when the patient’s adverse 
reactions are severe. The early use of systemic corti-
costeroids should be beneficial in treating TEN pa-
tients when there is no clinical contraindication to 
their use [5,8]. 
Several studies have investigated the risk factors for 
the development of lamotrigine-associated skin rash, 
SJS or TEN. The results showed that the incidence of 
skin rash might be increased in the following condi-
tions: (1) exceeding the recommended initial dosage 
of lamotrigine, for example, 50 mg daily or above; (2) 
exceeding and relatively rapid escalation of the recom-
mended dosage for lamotrigine; (3) coadministration 
of lamotrigine with valproate; (4) use in the pediatric 
population, age younger than 13 years; (5) a previ-
ous history of another anticonvulsant drug-related 
rash. The last condition could pose the greatest risk 
[9,13,15–18]. Therefore, the concomitant use of lamo-
trigine and other drugs for epilepsy or bipolar disor-
der should be very carefully designed because of the 
possibility of drug interaction as well as lamotrigine’s 
different dosing schedule [9].
In conclusion, clinicians should be aware that lamo-
trigine treatment can produce life-threatening adverse 
reactions, particularly in patients on concurrent dos-
ages of valproate and in pediatric patients.
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